3.71
Schlusskurs vom Vortag:
$3.63
Offen:
$3.63
24-Stunden-Volumen:
2.52M
Relative Volume:
1.32
Marktkapitalisierung:
$636.06M
Einnahmen:
$25.55M
Nettoeinkommen (Verlust:
$-341.97M
KGV:
-1.325
EPS:
-2.8
Netto-Cashflow:
$-304.44M
1W Leistung:
+6.00%
1M Leistung:
+16.30%
6M Leistung:
-24.59%
1J Leistung:
-57.84%
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
399 BINNEY STREET, CAMBRIDGE
Vergleichen Sie RLAY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RLAY
Relay Therapeutics Inc
|
3.71 | 600.06M | 25.55M | -341.97M | -304.44M | -2.80 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-17 | Eingeleitet | Wells Fargo | Equal Weight |
2024-09-10 | Fortgesetzt | Goldman | Buy |
2024-09-10 | Hochstufung | Jefferies | Hold → Buy |
2024-09-10 | Herabstufung | Oppenheimer | Outperform → Perform |
2024-05-10 | Hochstufung | Barclays | Equal Weight → Overweight |
2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
2023-04-13 | Eingeleitet | Raymond James | Outperform |
2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
2022-09-30 | Eingeleitet | Barclays | Equal Weight |
2022-09-02 | Eingeleitet | Stifel | Buy |
2022-06-06 | Eingeleitet | Jefferies | Underperform |
2022-02-01 | Eingeleitet | Berenberg | Buy |
2021-07-21 | Eingeleitet | BofA Securities | Buy |
2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
2020-08-10 | Eingeleitet | Cowen | Outperform |
2020-08-10 | Eingeleitet | Goldman | Buy |
2020-08-10 | Eingeleitet | Guggenheim | Buy |
2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
What analysts say about Relay Therapeutics Inc. stockExceptional return forecasts - jammulinksnews.com
Relay Therapeutics Inc. Stock Analysis and ForecastExceptional earning trajectories - jammulinksnews.com
What drives Relay Therapeutics Inc. stock priceFree Daily Trading Room Entry - Autocar Professional
Is Relay Therapeutics Inc. a good long term investmentUnprecedented growth rates - jammulinksnews.com
Why Relay Therapeutics Inc. stock attracts strong analyst attentionLow Risk High Reward Picks - Newser
what makes relay therapeutics inc. stock price move sharplyTargeted 200 Percent Gain - Newser
Is Relay Therapeutics Inc. stock overhyped or has real potentialLong Term Secure Gain Stocks - Newser
Is Relay Therapeutics Inc. stock a good hedge against inflationFree Stock Market Insider Analysis - Newser
RLAY’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - The Globe and Mail
How Relay Therapeutics Inc. stock performs during market volatilityFree Real-Time Trading Opportunities - Newser
What makes Relay Therapeutics Inc. stock price move sharplyTrade Ready Signal - Newser
DekaBank Deutsche Girozentrale Raises Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Have Relay Therapeutics Insiders Been Selling Stock? - simplywall.st
Wealth Enhancement Advisory Services LLC Makes New $41,000 Investment in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
AI drug discovery platform Market May See a Big Move | Major Giants - openPR.com
Relay Therapeutics CEO Patel sells $219k in shares By Investing.com - Investing.com Canada
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? - The Globe and Mail
Relay Therapeutics: A Biotech Breakthrough with Momentum - AInvest
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology - PR Newswire
Unraveling Relay Therapeutics' 9.8% Spike: A Closer Look at the Anomaly - AInvest
In the Green: Relay Therapeutics Inc (RLAY) Closes at 3.06, Up/Down -6.42 from Previous Day - DWinneX
Relay Therapeutics’ SWOT analysis: AI-driven drug discovery stock faces pivotal phase - Investing.com India
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by California State Teachers Retirement System - Defense World
# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com India
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors | RLAY Stock News - GuruFocus
Relay Therapeutics Appoints Claire Mazumdar to Board of Directors - citybiz
# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial By Investing.com - Investing.com South Africa
Relay Therapeutics Appoints Claire Mazumdar To Board Of Directors - MarketScreener
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - Bluefield Daily Telegraph
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 9,293 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):